Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Clin Microbiol Rev. 2004 Oct;17(4):783-93, table of contents.

Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis.

Author information

  • 1Division of Biochemistry, Microbiology, and Immunology, Faculty of Mediine, University of Ottawa, Ontario, Canada.

Abstract

Infections with the sexually transmitted protozoan Trichomonas vaginalis are usually treated with metronidazole, a 5-nitroimidazole drug derived from the antibiotic azomycin. Metronidazole treatment is generally efficient in eliminating T. vaginalis infection and has a low risk of serious side effects. However, studies have shown that at least 5% of clinical cases of trichomoniasis are caused by parasites resistant to the drug. The lack of approved alternative therapies for T. vaginalis treatment means that higher and sometimes toxic doses of metronidazole are the only option for patients with resistant disease. Clearly, studies of the treatment and prevention of refractory trichomoniasis are essential. This review describes the mechanisms of metronidazole resistance in T. vaginalis and provides a summary of trichomonicidal and vaccine candidate drugs.

PMID:
15489348
[PubMed - indexed for MEDLINE]
PMCID:
PMC523556
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk